Fassmer, Greenboats partner to enhance natural fiber development

Photo Credit: Greenboats Fiber composite technology company Fassmer (Berne, Germany) and Greenboats (Bremen, Germany) announce a formal partnership to enhance sustainable manufacturing technologies in Germany. Greenboats will establish the production of its ecological composite materials at Fassmer’s facility, thus creating a globally distinctive manufacturing site, distinguished by its production scope and sustainability. This cooperation merges Fassmer’s decades of experience in composite technologies with Greenboats’ expertise in developing natural fiber composites. As part of the agreement, a production facility, designed to manufacture natural fiber-reinforced composite laminates up to 6 × 2.5 meters, and characterized by the use of eco-friendly flax fibers and bio-based resins, will be constructed. It will ultimately produce products with significantly reduced CO2 footprints and set recycling benchmarks. Both companies highlight the significance of the partnership between Greenboats and Fassmer in industrializing new materials and meeting the increasing demand for sustainable products. Friedrich J. Deimann, founder and CEO of Greenboats, stresses the need for foresight, courage and strong partnerships to achieve ambitious goals, while Sven Sperling, director of operations for Fassmer, emphasizes combining experience, consistency and high quality with innovation and sustainability to tackle future challenges and provide a sustainable product portfolio to customers.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.